Skip to content
A customized process isolator specifically designed for powder handling, featuring a large stainless steel vessel and sensors for precision manufacturing.

Aseptic handling of toxic powders & specialized processes in isolators

The entire process chain – from API processing to fill-finish

Learn more

Before a sterile drug product is filled, it often goes through several open process steps: the API is introduced, weighed, transferred, then formulated. Traditionally, this takes place in the cleanroom, with personnel working directly at the product. As a result, more and more manufacturers are moving these steps into isolators.

What makes this demanding is the fact that these processes are highly product-specific. With highly potent APIs, the isolator must also protect both product and personnel at the same time. This article shows what matters along the process chain.

How the API becomes a ready-to-fill product

The process chain at a glance

  • Not every process goes through all the steps. Which building blocks are needed depends on the product.

  • 1

    Material introduction

    API containers, components, and materials are brought into the isolator via airlocks or transfer ports and decontaminated in the process.

  • 2

    Opening, weighing and dispensing

    The containers are opened and the API is precisely weighed or dispensed. From this point on, the API is exposed.

  • 3

    Transfer

    The API is transferred into a process vessel via a closed transfer system.

  • 4

    Formulation or homogenization

    For liquid products, the API is dissolved and mixed with buffers or solvents. If it is filled as a powder, it is only homogenized.

  • 5

    Handover

    The product is passed on via validated interfaces to sterile filtration, bulk storage, or filling.

Why these processes are particularly demanding

Sterility meets containment

  • Challenging powders

    Flow behavior, dust generation, and adhesion complicate every handling step and every transfer.

  • More powder processes

    Sterile filter drying is gaining importance over freeze-drying, and APIs are then processed further as powders.

  • Highly potent APIs

    Highly potent APIs, such as oncology drugs or antibody-drug conjugates (ADCs), require a high level of operator protection in addition to product protection.

  • Conflicting pressure requirements

    Aseptic processing requires positive pressure, while operator protection traditionally requires negative pressure. A product- and process-specific risk analysis determines which pressure regime an isolator is given.

When an API is considered highly potent

OEB, OEL and PDE

There is no uniform definition. Since the EMA guideline on shared facilities, a permitted daily exposure (PDE) value must be established for every API. Occupational exposure limits (OEL) and occupational exposure bands (OEB) are derived from this.The containment pyramid differentiates between six bands. From OEB 3 onward – i.e., a PDE of 1 mg per day or less – a substance is considered highly potent. That is roughly the limit of what is still visible to the naked eye.

Read whitepaper about containment
Steps 1 to 3 in detail

Critical moments in powder handling

Hotspot image
  • Rapid decontamination airlock

    The outside of the containers is decontaminated with H₂O₂. Interlocked doors keep the isolator closed at all times.

  • Preparation chamber

    This is where the containers are opened. Critical: the inside of the closure has already been in contact with the product.

  • Integrated scale

    Gross and net weight are recorded directly in the isolator without having to remove the container.

  • Discharge chamber

    Docking and discharging carry the greatest risk of dust release. A pressure cascade and directed airflow keep dust within this chamber.

  • Protected return air

    Sealable filter cartridges keep the API out of hard-to-clean return-air ducts.

    More about filters
  • Material removal

    The empty container still holds an air-dust mixture. It is sealed and removed via a dedicated airlock.

Sterile powder transfer

  • Transferring powder into the isolator or from the isolator into a process vessel requires a connection that is sterile, tight, and reliably repeatable. The common solution is the split butterfly valve. Depending on the process, an airlock or a Rapid Transfer Port (RTP) may also be an option.

  • One valve half is mounted on the isolator and the other on the container. When docked, the two halves combine to form a single closed disc that opens as one. The system is compact and easy to automate. Poorly flowing powders can cause bridging.

  • The previously sterilized container is docked to a port on the isolator. When the doors are opened, containment and aseptic conditions are maintained, and the powder is transferred through the port. The critical element is the Ring of Concern: the narrow seal area that was exposed to the environment before docking. Whether an RTP is suitable for powder transfer is therefore assessed through a risk analysis.

  • The key factors are the flow behavior and potency of the API, the sterilizability of the interface, changeover frequency, and the degree of automation. Which system is the right fit is determined by the risk analysis for the specific process.

Step 4 in detail

Formulation in the isolator

Once the API is in the process vessel, formulation usually follows. Isolators for this purpose are still rare but are gaining importance. Here, the isolator is built around the process equipment:

  • Scales, mixing vessels, and magnetic stirrers
  • Peristaltic pumps for dosing
  • Aseptic fluid connections for liquid starting materials
  • Single-use systems

Access from both sides and multiple airlocks enable parallel work without interrupting production.

More about formulation isolators
BioM formulation isolators case story video.
What robotics contribute to aseptic processing

Automation across the entire chain

Robots can take over individual steps or the entire chain, from opening the containers and weighing to docking and discharging. They remove people – the greatest source of contamination – from the process and protect personnel from highly potent substances. To operate in Grade A, robots must:

  • Release hardly any particles
  • Have smooth, crevice-free, H₂O₂-resistant surfaces
  • Move during decontamination so that all surfaces are reached
  • Disturb the airflow as little as possible

Stop safely via light curtains during glove interventions

Watch video
Internal view of an aseptic isolator featuring a robotic arm and specialized machinery for automated pharmaceutical powder handling in a sterile environment - by SKAN.

Cleaning and decontamination to prevent cross-contamination

Cleaning

In multi-product facilities, no residues may carry over into the next campaign. After each campaign, the chambers are cleaned automatically. PDA proposes OEB-based limits for surfaces and air.

Decontamination

Closed filter cartridges reduce the volume to be decontaminated. With catalytic H₂O₂ breakdown, a complete cycle in less than 90 minutes is possible.

What this means for planning

Key takeaways

  • Process first

    The API, powder, throughput, and product changeovers determine the isolator concept.

  • Combine protection

    Chambers, pressure cascades, and protected return air combine product and operator protection.

  • Choose the right transfer system

    The transfer system follows from the powder, the process, and the risk analysis.

  • Simulate early

    Risk analysis and airflow simulation (CFD) belong at the start of the project – especially when robotics are involved.

What requirements does your process place on the isolator?

Talk to our experts about your application. 

Back to top